Hypertrophic cardiomyopathy (HC) is associated with a well-recognized risk for unexpected sudden death (SD). Most such reported patients have been referred to dedicated centers and/or expert cardiologists for risk stratification, with the number of SDs decreasing sharply due to penetration of the implantable cardioverter-defibrillator (ICDs) into HC practice. However, the clinical circumstances, and morphologic features of HC patients who incur SD without the opportunity to be considered for preventive intervention with ICDs are largely undefined. Using the long-standing unique Jesse Edwards Registry (St. Paul, Minnesota), we studied 86 selected heart specimens from young HC patients who died suddenly and unexpectedly without prior clinical evaluation, ages 31 ± 16 years. The patients were predominantly male (87%) with only modest phenotypic expression and maximum LV wall thickening of only 18 ± 4 mm. SD events occurred predominantly with sedentary/mild activities (66%) often in bed or asleep (32%), but also during physical activity (22%) including with organized competitive sports. This largely unappreciated sub-population of patients with HC (and SD) is characterized by mild-to-moderate degree of LV hypertrophy, representing a clinical challenge which is particularly relevant in the current ICD era for HC, with the potential for SD prevention.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjcard.2020.04.021DOI Listing

Publication Analysis

Top Keywords

hypertrophic cardiomyopathy
8
sudden death
8
patients
5
cardiomyopathy sudden
4
death initially
4
initially identified
4
identified autopsy
4
autopsy hypertrophic
4
cardiomyopathy associated
4
associated well-recognized
4

Similar Publications

Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies.

View Article and Find Full Text PDF

Study Objective: Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome.

View Article and Find Full Text PDF

The year 2024 has seen significant progress in the management of heart failure. New treatments have demonstrated their efficacy, particularly for heart failure with preserved ejection fraction, cardiac amyloidosis, and hypertrophic cardiomyopathy. Advances in imaging, such as MRI and PET-CT, highlight the growing integration of innovative technologies and artificial intelligence in cardiology for diagnosing complex cardiovascular diseases.

View Article and Find Full Text PDF

Cardiac MRI Evaluation of Heart Failure and Cardiomyopathies.

R I Med J (2013)

February 2025

Brown University Health Cardiovascular Institute; Rhode Island, the Miriam and Newport Hospitals; Warren Alpert Medical School, Brown University.

Cardiac magnetic resonance imaging (CMR) is an exciting noninvasive imaging modality with increasing utilization in the field of cardiovascular medicine. In conjunction with echocardiogram, computed tomography, and invasive therapies, CMR has provided exceptional capability to further evaluate complex clinical cardiac conditions. CMR provides both anatomical and physiological information of a variety of tissue types, without the need for ionizing radiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!